Female Cosmetic Genital Surgery (FGCS)
This page covers the elective / aesthetic end of female genital surgery — labiaplasty, clitoral hoodoplasty, labia majora augmentation, monsplasty, surgical vaginoplasty / energy-based devices, hymenoplasty, and regenerative / fat-grafting techniques. Reconstructive operations for trauma, oncologic resection, lichen sclerosus, FGM/C, or congenital anomaly live at 04e Genital Reconstruction; gender-affirming pathway surgery lives at 04k Gender-Affirming Surgery.
Society positions and evidence-quality caveat. The ACOG 2020 Committee Opinion and the FIGO 2025 Statement assert that female genital cosmetic procedures are not medically indicated in patients without structural or functional abnormalities, and the FDA 2018 safety communication warned against use of energy-based devices for "vaginal rejuvenation" or cosmetic indications — no such device is FDA-cleared for these uses.[1][2][4] The SMSNA 2024 position statement notes the parallel point on the male side: the overall evidence quality for cosmetic penile-enhancement procedures is low and most should be considered investigational. Mandatory psychological screening for body dysmorphic disorder (BDD) belongs at the front of every consultation.[3]
Decision Framework
The female cosmetic-genital-surgery plan operates under explicit cautions from professional societies. ACOG 2020 (Committee Opinion) states that procedures to alter sexual appearance or function (excluding clinical indications) are not medically indicated, pose substantial risk, and have not had safety / effectiveness established.[1] FIGO 2025 asserts it is ethically inappropriate for obstetrician-gynecologists to recommend, perform, or refer cosmetic genital procedures in women without structural / functional abnormalities.[4] The FDA 2018 safety communication warned against use of energy-based devices for "vaginal rejuvenation" — no device has been FDA-cleared / approved for cosmetic indications.[2] These positions contrast with growing outcome data showing 94–99% pooled patient satisfaction across labiaplasty techniques and significant improvements in genital self-image and symptom resolution. The contemporary anchors are the Escandón 2022 PRS meta-analysis of labiaplasty (94–99% satisfaction; complication 4.7% wound dehiscence), the Géczi 2024 Aesthet Surg J comprehensive labiaplasty meta (technique-level satisfaction + risk), the Sorice-Virk 2020 PRS prospective n = 62 (mean 6.5 of 11 symptoms preoperatively → 93.5% symptom-free postop), the Sharp 2016 PRS prospective psychological-outcomes study (preoperative distress predicts lower satisfaction; p = 0.001), the Goodman 2010 large multicenter outcome study (n = 258; 91.6% satisfaction), the Liu 2022 clitoral-hood classification system (n = 789; 95.7% satisfaction; revision 1.9%), and the Pereira 2024 J Sex Med systematic review of vaginal-laxity treatment (RCTs do not confirm efficacy of energy-based devices).[5][6][7][8][9][10][11][12][13]
Mandatory Pre-Procedural Assessment
| Assessment | Action |
|---|---|
| Counseling on normal anatomic variation | Reassure that vulvar size, shape, and color vary widely and are further modified by puberty, aging, childbirth, and menopause. Reassurance about normal anatomy is the essential first step (ACOG 2020).[1] |
| Distinguish functional vs purely cosmetic indication | Document specific symptoms (chafing, tugging, pain with exercise / intercourse, hygiene). 52.4% of one large cohort reported functional impairment, 27.3% reported both; Sorice-Virk 2020 prospective n = 62 averaged 6.5 of 11 symptoms preoperatively. |
| BDD screening | Use validated tool (BDDQ-AS or BDD-YBOCS); if positive, refer to psychiatry before surgery. Cosmetic-surgery cohort BDD prevalence ~11.3%.[1][3] |
| Psychological-distress assessment | Higher preoperative distress predicts lower postop satisfaction (Sharp 2016 PRS, p = 0.001). |
| Informed consent | Discuss investigational nature per ACOG / FIGO; potential complications (pain / bleeding / infection / scarring / adhesions / altered sensation / dyspareunia / reoperation); lack of high-quality evidence for most procedures. |
Identify the Clinical Goal
| Patient Concern | Primary Procedure Category | Evidence Level |
|---|---|---|
| Labia minora protrusion (functional ± aesthetic) | Labiaplasty (trim or wedge or de-epithelialization) | Moderate–High (multiple meta-analyses, 1 RCT) |
| Clitoral-hood redundancy | Clitoral hoodoplasty (usually combined with labiaplasty) | Low–Moderate (large case series; Liu 2022 classification) |
| Labia majora atrophy / deflation | Fat grafting to labia majora | Low (case series) |
| Labia majora excess (post-massive weight loss) | Labia majora reduction (excision) | Very Low (case reports) |
| Mons pubis ptosis / excess | Monsplasty (excision ± liposuction ± fat grafting) | Very Low (case series) |
| Vulvovaginal atrophy (GSM) | Microfat / nanofat grafting; or energy-based devices via the canonical Vaginal Laser Therapy page | Low–Moderate |
| Hymen restoration | Hymenoplasty | Very Low (single retrospective series) |
| G-spot enhancement | G-spot amplification (HA injection) | Virtually none — safety / effectiveness not established |
Technique Selection by Procedure Category
Labiaplasty: Trim vs Wedge vs De-Epithelialization
| Factor | Trim Resection | Wedge Resection | De-Epithelialization |
|---|---|---|---|
| Best for | Irregular / darkened edge; all morphologies | Central protrusion; preserve natural edge / color transition | Mild hypertrophy; preserve volume |
| Pooled satisfaction | 94–99% (Escandón 2022 meta) | 94–99% | 97% (highest) — Géczi 2024 meta |
| Wound-dehiscence rate | Low | 3–8% | Lowest |
| Smoker / cocaine user | Acceptable | Contraindicated (higher dehiscence risk) | Acceptable |
| Edge appearance | Scar along free margin | Preserves natural edge | Preserves natural edge |
| Surgeon experience needed | Lower | Higher | Moderate |
| Decision rule (Zahedi 2023 algorithm) | Patient desires removal of darkened / irregular edge → Trim | Patient wants preserved natural edge / color transition → Wedge | Mild hypertrophy with desire to preserve volume → De-epithelialization |
Energy-Based Devices for GSM / "Rejuvenation"
Energy-based devices (fractional CO₂, Er:YAG, RF ± PEMF) are not FDA-cleared for cosmetic vaginal "rejuvenation" or for GSM (FDA 2018 Safety Communication). The Li 2021 JAMA sham-controlled RCT showed no significant benefit of fractional CO₂ over sham at 12 months — the highest-quality evidence available. Numerous uncontrolled observational series report benefit; the discrepancy implies a substantial placebo effect. ACOG 2020 and ESSM 2020 conclude evidence is insufficient. Cost is high ($1,800–9,000 per CO₂ course) and not insurance-covered. For full cross-indication evidence (GSM / SUI / lichen sclerosus / vaginal laxity / breast-cancer survivors) see the canonical Vaginal Laser Therapy page.
Combined Procedures
Multiple procedures are frequently performed simultaneously to achieve a harmonious result. Combined procedures increase operative time, anesthetic exposure, and cumulative complication risk — counsel patients accordingly.[8][14][15]
- Labiaplasty + clitoral hoodoplasty — most common combination; prevents residual hood sagging after isolated labiaplasty (Liu 2022; Eserdağ 2021 inverted-Y; Xia 2021 three-step composite).
- Labiaplasty + labia majora augmentation — addresses the labia majora–to–minora ratio; allows more conservative labial reduction (Hersant 2018 n = 21).
- "Genital beautification" packages — labia minora reduction + labia majora augmentation + mons liposuction ± laser brightening ± vaginal tightening (Cihantimur 2013; Toplu 2021; Cihantimur 2021 360 fat transfer n = 97).
Special Decision Branch — Clitoral Hoodoplasty
Frequently performed concurrently with labiaplasty. Liu 2022 Aesthet Plast Surg classification (Zone C central / Zone L lateral / standard / central / lateral / composite / special) drives technique selection.[16]
| Anatomy | Technique | Outcome |
|---|---|---|
| Vertical and / or horizontal central redundancy | Inverted-Y plasty (Eserdağ 2021 n = 63) | 96.9% satisfaction at 2 mo |
| Horizontal redundancy | Bilateral triangular skin resection | per Liu classification |
| Vertical redundancy | Inverted horizontal V-shaped resection | per Liu classification |
| Composite (lateral hood + labia minora) | Three-step excision (Xia 2021 n = 136) or two-part excision (Duan 2025 n = 68) | 95.5% / 92.6% satisfaction respectively |
| Liu 2022 classification-based (any anatomy) | Tailored technique per zone | 95.7% satisfaction; complications 4.3%; revision 1.9% (n = 789) |
Critical safety note: the clitoris must be carefully identified and protected during all hoodoplasty procedures to avoid injury to the dorsal nerve of the clitoris, which could result in permanent loss of sensation.
Postoperative Management
- Activity restriction: avoid intercourse, tampon use, and strenuous exercise × 4–6 weeks.
- Wound care: sitz baths, topical antibiotic ointment, loose-fitting clothing.
- Ice application: first 48–72 hours to reduce edema.
- Follow-up cadence: 1 week (wound check), 6 weeks (clearance for activity), 3–6 months (final outcome assessment).
- PRO assessment: FSFI at baseline and 6 months postoperatively; FGSIS or GAS at baseline and 6 months.
- Maintenance counseling: HA filler will resorb over time; energy-based device maintenance sessions may be required.
Complication Management
| Complication | Incidence | Management |
|---|---|---|
| Wound dehiscence | 3–8% (highest with wedge and laser) | Conservative; secondary closure if needed |
| Asymmetry | 1.4–6.3% | Observation (may improve with edema resolution); revision if persistent |
| Hematoma | 0.5–8% (highest with W-shape) | Observation if small; drainage if expanding |
| Infection | Rare | Antibiotics; wound care |
| Flap necrosis (wedge) | Very rare (3 cases in meta of 3,804) | Debridement; secondary healing or revision |
| Altered sensation | Reported but not quantified | Usually transient; permanent loss rare |
| Over-resection | Rare | Revision with local flaps or grafts; prevention is key |
| Patient dissatisfaction despite normal outcome | 1.6–8.9% | Re-evaluate for BDD; refer to psychiatry; AVOID repeat procedures |
Treatment Database
| Procedure | Domain |
|---|---|
| Trim Labiaplasty | Labiaplasty |
| Wedge Labiaplasty | Labiaplasty |
| De-Epithelialization Labiaplasty | Labiaplasty |
| Laser-Assisted Labiaplasty | Labiaplasty |
| Combined Wedge-Edge Resection | Labiaplasty |
| Inverted-Y Plasty Clitoral Hoodoplasty | Clitoral Hoodoplasty |
| Bilateral Triangular / Inverted-V Resection (Liu) | Clitoral Hoodoplasty |
| Three-Step / Two-Part Composite Excision | Clitoral Hoodoplasty |
| Labia Majora Augmentation (Autologous Fat Grafting) | Labia Majora |
| Labia Majora Reduction (Majoraplasty) | Labia Majora |
| Monsplasty | Mons Pubis |
| Fat Grafting to Mons Pubis | Mons Pubis |
| Vaginal Laser Therapy (Fractional CO₂ / Er:YAG / RF) | Energy-Based Devices |
| Hymenoplasty | Hymenoplasty / G-Spot |
| G-Spot Amplification | Hymenoplasty / G-Spot |
| Microfat + Nanofat Grafting | Regenerative |
See Also
- Male Cosmetic Genital Surgery
- Genital Reconstruction Atlas (non-cosmetic)
- Gender-Affirming Surgery
- Prolapse Repair — Posterior Colporrhaphy
- Foundations — V-Y Advancement Flap
References
1. American College of Obstetricians and Gynecologists. Elective female genital cosmetic surgery (Committee Opinion). 2020.
2. US Food and Drug Administration. Statement on efforts to safeguard women's health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for "vaginal rejuvenation". FDA Safety Communication. 2018.
3. Mansfield AK. Genital manifestations of body dysmorphic disorder in men: a review. Fertil Steril. 2020;113(1):16–20. doi:10.1016/j.fertnstert.2019.11.028
4. Capito L, Antsaklis A, Gupte S. FIGO Statement: cosmetic genital surgery. Int J Gynaecol Obstet. 2025;170(1):11–14. doi:10.1002/ijgo.70203
5. Escandón JM, Duarte-Bateman D, Bustos VP, et al. Maximizing safety and optimizing outcomes of labiaplasty: a systematic review and meta-analysis. Plast Reconstr Surg. 2022;150(4):776e–788e. doi:10.1097/PRS.0000000000009552
6. Géczi AM, Varga T, Vajna R, et al. Comprehensive assessment of labiaplasty techniques and tools, satisfaction rates, and risk factors: a systematic review and meta-analysis. Aesthet Surg J. 2024;44(11):NP798–NP808. doi:10.1093/asj/sjae143
7. Sorice-Virk S, Li AY, Canales FL, Furnas HJ. Comparison of patient symptomatology before and after labiaplasty. Plast Reconstr Surg. 2020;146(3):526–536. doi:10.1097/PRS.0000000000007081
8. Sharp G, Tiggemann M, Mattiske J. Psychological outcomes of labiaplasty: a prospective study. Plast Reconstr Surg. 2016;138(6):1202–1209. doi:10.1097/PRS.0000000000002751
9. Goodman MP, Placik OJ, Benson RH, et al. A large multicenter outcome study of female genital plastic surgery. J Sex Med. 2010;7(4 Pt 1):1565–1577. doi:10.1111/j.1743-6109.2009.01573.x
10. Liu M, Li Q, Li S, et al. Preliminary exploration of a new clitoral-hood classification system and treatment strategy. Aesthet Plast Surg. 2022;46(6):3080–3093. doi:10.1007/s00266-022-02874-y
11. Pereira GMV, Cartwright R, Juliato CRT, et al. Treatment of women with vaginal laxity: systematic review with meta-analysis. J Sex Med. 2024;21(5):430–442. doi:10.1093/jsxmed/qdae028
12. Qiang S, Li FY, Zhou Y, et al. Long-term follow-up in labiaplasty in 414 women: a single-center experience in China. Ann Plast Surg. 2022;89(4):353–357. doi:10.1097/SAP.0000000000003264
13. Zahedi S, Bhat D, Pedreira R, Canales FL, Furnas HJ. Algorithm for trim and wedge labiaplasties. Aesthet Surg J. 2023;43(6):685–692. doi:10.1093/asj/sjad033
14. Cihantimur B, Herold C. Genital beautification: a concept that offers more than reduction of the labia minora. Aesthet Plast Surg. 2013;37(6):1128–1133. doi:10.1007/s00266-013-0211-4
15. Cihantimur B, Aglamis O, Ozsular Y. 360 genital fat transfer. Aesthet Plast Surg. 2021;45(6):2996–3002. doi:10.1007/s00266-021-02488-w
16. Eserdağ S, Anğın AD. Surgical technique and outcomes of inverted-Y plasty procedure in clitoral-hoodoplasty operations. J Minim Invasive Gynecol. 2021;28(9):1595–1602. doi:10.1016/j.jmig.2021.01.015